These 4 Dividend Stocks Offer Tempting Yields. But the Warning Signs Are Getting Harder to Ignore24/7 Wall Street • 10/11/26
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up24/7 Wall Street • 10/09/26
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowZacks Investment Research • 10/09/26
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks24/7 Wall Street • 10/09/26
Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)Seeking Alpha • 10/09/26
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/09/26
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsZacks Investment Research • 10/08/26
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/08/26
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerZacks Investment Research • 10/08/26
Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next.The Motley Fool • 10/08/26
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not24/7 Wall Street • 10/08/26
Pfizer's TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerBusiness Wire • 10/07/26
Astellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026PRNewsWire • 10/06/26